Wide excision with careful attention to hearing preservation is attempted, although tumor size and extent may limit the ability to achieve complete removal. All patients with VHL should be radiographically screened for ELSTs. If bilateral tumors are present, they are almost always associated with VHL. The tumors will frequently expand into the posterior cranial fossa, ranging up to 10 em in greatest dimension.
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5.4Immunosuppression
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Hypothalamic-Pituitary-Adrenal Axis Effect
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Nursing Mothers
It is not known if ciclesonide isexcreted in human milk. However, other corticosteroids are excreted in human milk. Inastudy with lactating rats, minimal but detectable levels of radlolabeled ciclesonide were recovered in milk. Caution should be used when ZETONNA Nasal Aerosol is administered to nursing women. 8.4Pediatric Use The safety and effectiveness forseasonal and perennial allergic rhinitis in children 12years ofage and older have been established. The safety and efficacy ofZETONNA Nasal Aerosol fortreatment ofthe symptoms ofseasonal and perennial allergic rhinitis in patients 11 years ofage and younger have not been established. Controlled clinical trials have shown that intranasal corticosteroids may cause a reduction ingrowth velocity in pediatric patients. This effect has been observed inthe absence of laboratory evidence of hypothalamicpituitary-adrenal (HPA)-axis suppression, suggesting that growth velocity is a more sensitive indicator ofsystemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA-axis function. The longterm effects ofthis reduction ingrowth velocity associated with intranasal corticosteroids, including the impact on final adult height, are unknown. The potential for"catch-up" growth following discontinuation oftreatment with intranasal corticosteroids has not been adequately studied. The growth ofpediatric patients receiving intranasal corticosteroids, including ZETONNA Nasal Aerosol, should be monitored routinely (e.g., via stadiometry). A 52-week, multi-center, double-blind, randomized, placebo-controlled parallelgroup trial was conducted to assess the effect of orally inhaled ciclesonide (ALVESCO® Inhalation Aerosol) on growth rate in609 pediatric patients with mild persistent asthma, aged 5to 8.5 years. Treatment groups included orally inhaled ciclesonide 40 meg or160 mcg or placebo given once daily. Growth was measured by stadiometer height during the baseline, treatment and follow-up periods. The primary comparison was the difference ingrowth rates between ciclesonide 40and 160 mcg and placebo groups. Conclusions cannot be drawn from this trial because compliance could not be assured. Ciclesonide blood levels were also not measured during the one-year treatment period. There was no difference inefficacy measures between the placebo and the orally inhaled ciclesonide (ALVESCO® Inhalation Aerosol) groups.
The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability ofsafe and effective noncorticosteroid treatment alternatives. To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to the lowest dose that effectively controls his/her symptoms. The potential forZETONNA Nasal Aerosol to cause growth suppression in susceptible patients orwhen given athigher than recommended dosages cannot be ruled out. 8.5Geriatric Use Clinical trials ofZETONNA Nasal Aerosol did notinclude sufficient numbers of patients age 65 and over to determine whether they responded differently from younger patients. Other reported clinical experience has not identified differences inresponses between the elderly and younger patients. Ingeneral, dose selection for an elderly patient should be cautious reflecting the greater frequency ofdecreased hepatic, renal, orcardiac function, and of concomitant disease orother drug therapy. 
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tinct cell borders. The nuclei are small, round, and hyperchromatic (figure 2). Pleomorphism, mitosis, and necrosis are nearly always absent. Metastatic adenocarcinoma, metastatic clear-cell renal cell carcinoma, and metastatic thyroid papillary carcinoma need to be eliminated by clinical, imaging, histologic, and immunohistochemical evaluation. Specifically, a renal cell carcinoma may be challenging, as renal cell carcinoma is a component of VHL. A choroid plexus papilloma is usually midline without temporal bone destruction. 
